ZOETIS ($ZTS) posted quarterly earnings results for Q4 2025 on Thursday, February 12th. The company reported earnings of $1.48 per share, beating estimates of $1.42 by $0.06. The company also reported revenue of $2,387,000,000, beating estimates of $2,383,604,585 by $3,395,415.
You can see Quiver Quantitative's $ZTS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ZOETIS Hedge Fund Activity
We have seen 618 institutional investors add shares of ZOETIS stock to their portfolio, and 1,198 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 5,474,210 shares (+12.9%) to their portfolio in Q4 2025, for an estimated $688,765,102
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,833,796 shares (+54.8%) to their portfolio in Q3 2025, for an estimated $414,641,030
- NORDEA INVESTMENT MANAGEMENT AB added 2,179,578 shares (+79.2%) to their portfolio in Q4 2025, for an estimated $274,234,503
- POLEN CAPITAL MANAGEMENT LLC removed 1,954,242 shares (-26.0%) from their portfolio in Q4 2025, for an estimated $245,882,728
- MONTRUSCO BOLTON INVESTMENTS INC. added 1,560,314 shares (+256.7%) to their portfolio in Q4 2025, for an estimated $196,318,707
- CORIENT PRIVATE WEALTH LLC removed 1,534,666 shares (-59.5%) from their portfolio in Q3 2025, for an estimated $224,552,329
- VICTORY CAPITAL MANAGEMENT INC removed 1,382,837 shares (-88.1%) from their portfolio in Q3 2025, for an estimated $202,336,709
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ZOETIS Government Contracts
We have seen $553,520 of award payments to $ZTS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- THIS IS A DELIVERY ORDER FOR WIRE TIES FOR THE USDA, AMS, COTTON AND TOBACCO PROGRAM; THIS IS THE FIRST DEL...: $503,000
- NM - NEW MEXICO ESFO - CHEMICAL IMMOBILIZATION DRUG (TELAZOL) FOR MEXICAN WOLF RECOVERY PROGRAM: $35,520
- RABIES VACCINES FOR OEHE WITH BASE AND FOUR OPTIONS: $15,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ZOETIS Congressional Stock Trading
Members of Congress have traded $ZTS stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ZTS stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/19, 11/18 and 0 sales.
- SENATOR MARKWAYNE MULLIN sold up to $50,000 on 11/10.
- REPRESENTATIVE RICK LARSEN sold up to $15,000 on 10/06.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ZOETIS Analyst Ratings
Wall Street analysts have issued reports on $ZTS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/12/2025
- Morgan Stanley issued a "Overweight" rating on 11/10/2025
- Argus Research issued a "Buy" rating on 09/09/2025
To track analyst ratings and price targets for ZOETIS, check out Quiver Quantitative's $ZTS forecast page.
ZOETIS Price Targets
Multiple analysts have issued price targets for $ZTS recently. We have seen 8 analysts offer price targets for $ZTS in the last 6 months, with a median target of $150.5.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $135.0 on 01/22/2026
- Glen Santangelo from Barclays set a target price of $136.0 on 12/09/2025
- Mark Massaro from BTIG set a target price of $160.0 on 12/03/2025
- Jonathan Block from Stifel set a target price of $130.0 on 11/18/2025
- Erin Wright from Morgan Stanley set a target price of $175.0 on 11/10/2025
- Chris Schott from JP Morgan set a target price of $200.0 on 11/05/2025
- Andrea Alfonso from UBS set a target price of $141.0 on 11/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
